Department of Cardio-Thoracic Surgery, Hunan Children's Hospital, Changsha, 410007, People's Republic of China.
Department of Ultrasound Medicine, Hunan Children's Hospital, Changsha, 410007, People's Republic of China.
Mol Med. 2021 Aug 13;27(1):88. doi: 10.1186/s10020-021-00353-9.
BACKGROUND: Atherosclerosis is recognized as a chronic immuno-inflammatory disease that is characterized by the accumulation of immune cells and lipids in the vascular wall. In this review, we focus on the latest advance regarding the regulation and signaling pathways of IL-22 and highlight its impacts on atherosclerosis. MAIN BODY: IL-22, an important member of the IL-10 family of cytokines, is released by cells of the adaptive and innate immune system and plays a key role in the development of inflammatory diseases. The binding of IL-22 to its receptor complex can trigger a diverse array of downstream signaling pathways, in particular the JAK/STAT, to induce the expression of chemokines and proinflammatory cytokines. Recently, numerous studies suggest that IL-22 is involved in the pathogenesis of atherosclerosis by regulation of VSMC proliferation and migration, angiogenesis, inflammatory response, hypertension, and cholesterol metabolism. CONCLUSION: IL-22 promotes the development of atherosclerosis by multiple mechanisms, which may be a promising therapeutic target in the pathogenesis of atherosclerosis.
背景:动脉粥样硬化被认为是一种慢性免疫炎症性疾病,其特征是免疫细胞和脂质在血管壁中的积累。在这篇综述中,我们重点介绍了白细胞介素 22(IL-22)的最新研究进展,及其对动脉粥样硬化的影响。
正文:白细胞介素 22(IL-22)是白细胞介素 10 家族细胞因子的重要成员,由适应性和固有免疫系统的细胞释放,在炎症性疾病的发展中发挥关键作用。IL-22 与受体复合物的结合可以触发多种下游信号通路,特别是 JAK/STAT,从而诱导趋化因子和促炎细胞因子的表达。最近的许多研究表明,IL-22 通过调节血管平滑肌细胞的增殖和迁移、血管生成、炎症反应、高血压和胆固醇代谢等多种机制参与动脉粥样硬化的发病机制。
结论:IL-22 通过多种机制促进动脉粥样硬化的发展,可能成为动脉粥样硬化发病机制中的一个有前途的治疗靶点。
Mol Med. 2021-8-13
Clin Chim Acta. 2014-4-20
Am J Physiol Heart Circ Physiol. 2013-5-31
J Autoimmun. 2019-2-14
Circ Res. 2012-8-27
J Immunol Res. 2019-12-1
Front Immunol. 2019-2-12
Front Immunol. 2025-1-29
Am J Transl Res. 2024-10-15
Cardiovasc Toxicol. 2024-6
Biomedicines. 2024-1-9
Int J Mol Sci. 2023-3-29
Front Endocrinol (Lausanne). 2023
Int J Mol Sci. 2021-5-21